Tested blood cancer medicine with hormone therapy for breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies SPH4336 given together with standard hormone (endocrine) therapy for breast cancer that has spread or cannot be treated with surgery. It aims to see whether the combination is safer and more effective than hormone therapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are willing to sign the informed consent form and understand the study.
- You are able to do most daily activities (ECOG score 0 to 1).
- Your expected survival is at least 3 months.
- Your breast cancer is locally advanced or metastatic, and surgery or other local treatments are not an option.
- You have at least one measurable tumor spot on scans or exams.
- Your blood work and organ function (like liver/kidney function) are acceptable for study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding SPH4336 to letrozole works better than letrozole plus a placebo for treating hormone-receptor–positive, HER2-negative breast cancer in people starting first-line treatment. It may help slow cancer growth more effectively if the added drug is beneficial.
This trial tests a new combination of drugs (HRS-8080 and dalpiciclib) for women with advanced or metastatic breast cancer that has stopped responding to initial hormone therapy after surgery. It aims to see if this combination is safe and effective.
This trial tests whether SPH4336, added to standard hormone (endocrine) therapy, can improve outcomes for people with breast cancer that has spread to the brain. It also looks closely at safety and side effects.
This early-stage study tests SPH5030 tablets in people with HER2-positive advanced solid tumors that have not responded to standard treatment or have no standard option. It aims to see whether the treatment can shrink tumors and is safe enough to move forward.
This study tests a new medication (SPH5030) for people with advanced colorectal or biliary tract cancer whose tumors have a specific marker called HER2. It may offer a treatment option if previous therapies have stopped working.
This early-phase study tests SPH4336 alone or combined with an immunotherapy drug called cadonilimab in people with advanced solid cancers that can’t be cured with surgery or local treatments. It aims to find out how safe it is and whether it can shrink tumors or control the disease.
Hear when a new Locally Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.